本研究为扩大GLP-1 RA治疗DR或糖尿病血管疾病的可能性提供了实验证据。 信源: He Xuemin,Wen Siying,Tang Xixiang et al. Glucagon-like peptide-1 receptor agonists rescued diabetic vascular endothelial damage through suppression of aberrant STING signaling.[J] .Acta Pharm Sin B, 2024, 14: 2613-2630....
There’s also a similar class of medications calleddualGLP-1/GIP receptor agonists. There’s currently one of these medications on the market. It’s calledtirzepatide(Mounjaro®). dual :双重的 How do GLP-1 agonists work? To understand how GLP-1 agonists work, it helps to understand how...
2.Novo’s Older GLP-1 Drug Slows Cognitive Decline in Phase IIb Alzheimer’s Trial.July 30, 2024.Nick Paul Taylor 3.Novo's GLP-1 liraglutide may protect brain from Alzheimer's, new study finds.By Darren Incorvaia Jul 30, ...
[27] Luli, Alex, et al. "Barriers to Obtaining GLP-1 Receptor Agonists and SGLT2 Inhibitors in a Free Clinic Population With Type 2 Diabetes and Cardiovascular Disease." Journal of Contemporary Pharmacy Practice 70.1 (2023): 9-13.[28] Mahtta, Dhruv, et al. "Utilization rates of SGLT2...
最新的抗肥胖药物靶向GLP-1受体,胰高血糖素样肽-1 受体(GLP1R)是一种在胰腺 β 细胞和大脑神经元上发现的受体蛋白,它通过增强胰岛素分泌参与控制血糖水平。 胰高血糖素样肽1受体激动剂(GLP-1 receptor agonists, 简称GLP-1肽),通过增强β胰腺细胞分泌胰岛素和抑制α胰腺细胞释放胰高血糖素来改善血糖控制。[5]...
[1]Ussher, J.R., Drucker, D.J. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol 20, 463–474 (2023). [2]Mitchel L. Zoler. Semaglutide Cuts Cardiovascular Events in Landma...
[6] Nørgaard, Caroline Holm et al. “Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers.” Alzheimer's & dementia (New York, N. Y.) vol. 8,1 e1226...
近日,北京中医药大学万瑾毅副研究员、姚海强副研究员与芝加哥大学Chun-Su Yuan终身讲席教授团队合作,在国际顶尖医学期刊《英国医学杂志》(BMJ)发表了题为:Comparative effectiveness of GLP-1 receptor agonists on glycemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network...
GLP-1受体激动剂:超越其胰腺作用 完整文献全文翻译地址 Abstract 摘要 Glucagon like peptide-1 (GLP-1) is an incretin secretory molecule. GLP-1 receptor agonists (GLP-1RAs) are widely used in the treatment of type 2 diabetes (T2DM) due to their attributes such as body weight loss, protection ...
随着2型糖尿病在育龄女性中变得越来越普遍,以及最近批准使用GLP-1受体激动剂(例如司美格鲁肽)治疗肥胖,暴露于这些药物的孕妇的数量可能会增加。 卡罗林斯卡学院、哈佛大学、斯坦福大学等机构的研究人员在 JAMA Internal Medicine 期刊发表了题为:Safety of GLP-1 Receptor Agonists and Other Second-Line Antidiabetics...